
Rakuten Aspyrian Stock
Tumor-targeted precision therapies
Sign up today and learn more about Rakuten Aspyrian Stock
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.
About Rakuten Aspyrian Stock
Rakuten Aspyrian is a privately funded clinical stage biotechnology company developing tumor-targeted precision therapies based on its proprietary platform Photoimmunotherapy. Photoimmunotherapy combines key advantages of antibody-mediated targeting of the cancer cells to achieve high tumor specificity, together with laser-activation of a biophysical mechanism that induces rapid cancer cell death with precision. Treatments with the Photoimmunotherapy platform lead to targeted and rapid tumor cell death by necrosis, with minimal effects on normal tissue. Rakuten Aspyrian is studying Photoimmunotherapy for use as a monotherapy and in combination with other drugs. Founded in 2013, the company is based in San Diego, California.
Investors
Rakuten
Lyft, Pinterest, Aura Financial Corporation, Cabify, Rakuten Aspyrian, BlueVine, Upstart, Azimo
SBI Group
Funding History
January 2015 | $8.4M |
---|---|
July 2015 | $4.3M |
March 2016 | $40.0M |
July 2017 | $15.1M |
August 2018 | $150M |
December 2018 | $134M |
Management
Chief Executive Officer
Hiroshi Mikitani
COO & President
Takashi Toraishi
Chief Technical Officer
Carlos A. Garcia
Finances and Operations
Agatha Martindale
Head of Chemistry
Lew Makings
Press
strictlyvc - Mar, 11 2016
StrictlyVC: March 11, 2016xconomy - Mar, 11 2016
West Coast Bio Roundup: Illumina, CRISPR, Orexigen, Ambry & Morefinsmes - Jul, 28 2015
Aspyrian Therapeutics Secures $4.25M in Series A Extension Financingbusinesswire - Apr, 30 2015
AmpliPhi BioSciences Announces M. Scott Salka as New CEObusinesswire - Apr, 30 2015
AmpliPhi BioSciences Announces M. Scott Salka as New CEOxconomy - Apr, 23 2015
Innovation Grants and Unsung Life Sciences Startups of San Diego | Xconomyfiercebiotech - Jan, 27 2015
Aspyrian raises $8.5M for cancer therapy; Insys gets orphan status; BioCryst gains FDA fast track;socaltech - Jan, 27 2015
Aspyrian Therapeutics Raise $8.5MEquityZen does not have an affiliation with, formal relationship with, or endorsement from any companies featured above. This profile is based on publicly available information and is intended to be informative in nature.
Some data provided by Crunchbase